New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer
详细信息    查看全文
  • 作者：Romain Cohen ; Magali Svrcek ; Chantal Dreyer ; Pascale Cervera…
  • 关键词：Microsatellite instability ; BRAF mutation ; Immune checkpoint ; PD ; 1 ; PD ; L1
  • 刊名：Current Oncology Reports
  • 出版年：2016
  • 出版时间：March 2016
  • 年：2016
  • 卷：18
  • 期：3
  • 全文大小：978 KB
  • 参考文献：1.Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50:113–30.CrossRef PubMed
    2.Dienstmann R, Guinney J, Delorenzi M, Reynies AD, Roepman P, Sadanandam A, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol. 2014;32(5s). Suppl; abstr 3511.
    3.Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. Kemp C, editor. PLoS Med. 2013;10:e1001453.PubMedCentral CrossRef PubMed
    4.••
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20. MMR deficiency predicts efficacy of immune checkpoint inhibition with PD-1 inhibitor pembrolizumab in colorectal and non-colorectal carcinomas. CrossRef PubMed
5.Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154:1805–13.PubMedCentral CrossRef PubMed
6.Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedCentral CrossRef PubMed
7.Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.PubMedCentral CrossRef PubMed
8.Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29:1261–70.CrossRef PubMed
9.Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. JNCI J Natl Cancer Inst. 2011;103:863–75.CrossRef PubMed
10.Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2010;21:772–80.CrossRef PubMed
11.Tougeron D, Sickersen G, Lecomte T, Mouillet G, Trouilloud I, Coriat R, et al. Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: an AGEO multicenter study. J Clin Oncol. 2014;32:5s. Suppl; abstr 3508.CrossRef
12.Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 2014;146:401–11.CrossRef PubMed
13.Dorard C, de Thonel A, Collura A, Marisa L, Svrcek M, Lagrange A, et al. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med. 2011;17:1283–9.CrossRef PubMed
14.Colas C, Coulet F, Svrcek M, Collura A, Fléjou J-F, Duval A, et al. Lynch or not Lynch? Is that always a question? Adv Cancer Res. 2012;113:121–66.CrossRef PubMed
15.Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293–300.PubMedCentral CrossRef PubMed
16.Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352:1851–60.CrossRef PubMed
17.Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.PubMed
18.Umar A, Boland CR, Terdiman JP, Chapelle A d l, Ruschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. JNCI J Natl Cancer Inst. 2004;96:261–8.CrossRef PubMed
19.Brueckl WM, Moesch C, Brabletz T, Koebnick C, Riedel C, Jung A, et al. Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. Anticancer Res. 2003;23:1773–7.PubMed
20.Des Guetz G, Mariani P, Cucherousset J, Benamoun M, Lagorce C, Sastre X, et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 2007;27:2715–9.PubMed
21.Koopman M, Kortman GAM, Mekenkamp L, Ligtenberg MJL, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–73.PubMedCentral CrossRef PubMed
22.Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z-Q, Lieu CH, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623–32.PubMedCentral CrossRef PubMed
23.••
Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322–30. In metastatic colorectal cancer, both MMR deficiency and BRAFV600E mutation confer poor prognosis. The poor prognosis of dMMR seens to be driven by BRAFV600E. PubMedCentral CrossRef PubMed
24.Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy cetuximab. Clin Cancer Res. 2013;19:4104–13.PubMedCentral CrossRef PubMed
25.Donnard E, Asprino PF, Correa BR, Bettoni F, Koyama FC, Navarro FC, et al. Mutational analysis of genes coding for cell surface proteins in colorectal cancer cell lines reveal novel altered pathways, druggable mutations and mutated epitopes for targeted therapy. Oncotarget. 2014;5:9199.PubMedCentral CrossRef PubMed
26.Giannakis M, Shukla S, Mu J, Nishihara R, Yamauchi M, Sukawa Y, et al. Comprehensive molecular characterization of colorectal cancer reveals genomic predictors of immune cell infiltrates. J Clin Oncol. 2015;33. Suppl; abstr 3505.
27.Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, et al. Correlation between density of CD8+ T cell infiltrates in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. Published Online First June 9, 2015.
28.Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4.CrossRef PubMed
29.Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.CrossRef PubMed
30.Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:1429–40.CrossRef PubMed
31.Lal N, Beggs AD, Willcox BE, Middleton GW. An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. OncoImmunology. 2015;4:e976052.PubMedCentral CrossRef PubMed
32.•
Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5:43–51. Colorectal cancers with MMR deficiency specifically upregulate several immune checkpoints, unlike tumors with proficient MMR system. PubMedCentral CrossRef PubMed
33.Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, et al. Diagnosis of constitutional mismatch repair-deficiency syndrome based on microsatellite instability and lymphocyte tolerance to methylating agents. Gastroenterology. Published Online First June 25, 2015.
34.Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.CrossRef PubMed
35.Capper D, Voigt A, Bozukova G, Ahadova A, Kickingereder P, von Deimling A, et al. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer: BRAF V600E immunohistochemistry in MSI-H colorectal cancer. Int J Cancer. 2013;133:1624–30.CrossRef PubMed
36.Cremolini C, Bartolomeo MD, Amatu A, Antoniotti C, Moretto R, Berenato R, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol. 2015; Published Online First July 7, 2015.
37.Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.CrossRef PubMed
38.André T, de Gramont A, Chibaudel B, Tijeras-Raballand A, Duval A, Hickish T, et al. MOSAIC study: actualization of overall survival (OS) with 10 years follow up and evaluation of BRAF. By GERCOR and MOSAIC investigators. Ann Oncol. 2014;25(4):iv167–209.CrossRef
39.Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem J-L, et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:862–73.CrossRef PubMed
40.Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, et al. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/alliance N0147. JNCI J Natl Cancer Inst. 2014;106:dju106.CrossRef PubMed
41.French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008;14:3408–15.PubMedCentral CrossRef PubMed
42.Gavin PG, Colangelo LH, Fumagalli D, Tanaka N, Remillard MY, Yothers G, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531–41.PubMedCentral CrossRef PubMed
43.Taieb J, Le Malicot K, Penault-Llorca F, Bouche O, Shi Q, Thibodeau S, et al. Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/− cetuximab: a pooled analysis of 3934 pts from the PETACC8 and N0147 trials. J Clin Oncol. 2015;33 (suppl; abstr 3507).
44.Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. JCO. 2011;29:2011–9.CrossRef
45.Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013;369:1023–34.CrossRef PubMed
46.Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S-E, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–75.CrossRef PubMed
47.Stintzing S, Jung A, Rossius L, Modest DP, Fischer von Weikersthal L, Decker T, et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. Eur Cancer Congress. 2013;Abstract 17.
48.Peeters M, Price TJ, Cervantes Ruiperez A, Sobrero A, Ducreux M, André T, et al. Impact of baseline covariates and prior therapy on the efficacy of second-line panitumumab (pmab) + FOLFIRI vs FOLFIRI treatment. Ann Oncol. 2014;25(4):iv167–209.
49.André T, Blons H, Mabro M, Chibaudel B, Bachet J-B, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24:412–9.CrossRef PubMed
50.De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753–62.CrossRef PubMed
51.Seymour MT, Brown SR, Middleton G, Maughan T, Richman S, Gwyther S, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. lancet Oncol. 2013;14:749–59.PubMedCentral CrossRef PubMed
52.Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O’Callaghan CJ, Marginean C, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744–53.CrossRef PubMed
53.•
Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015;112:1888-94. In this meta-analysis, the hazard ratio for OS benefit with anti-EGFR monoclonal antibodies was 0.97 (95% CI; 0.67–1.41) for BRAF V600E tumors whereas the hazard ratio was 0.81 (95% CI; 0.70–0.95) for RAS WT /BRAF WT mCRC. However the test of interaction was not statistically significant. Thus there is insufficient data to justify the exclusion of anti-EGFR therapies for patients with RAS WT /BRAF V600E mCRC.
54.Seligmann J, Fisher D, Elliott F, Richman S, Butler R, Cheadle J, et al. Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): analysis from 2,530 patients (pts) in randomized clinical trials (RCTs). J Clin Oncol. 2015;33 (suppl; abstr 3509).
55.Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–52.CrossRef PubMed
56.Salvatore L, Loupakis F, Cremolini C, Schirripa M, Masi G, Antoniotti C, et al. FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutant metastatic colorectal cancer patients. J Clin Oncol. 2012;30 suppl; abstr 3585.
57.Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.CrossRef PubMed
58.Loupakis F, Cremolini C, Lonardi S, Tomasello G, Ronzoni M, Zaniboni A, et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol. 2014;32:5s (suppl; abstr 3519).
59.•Loupakis F, Cremolini C, Antoniotti C, Lonardi S, Ronzoni M, Zaniboni A, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): updated survival results and final molecular subgroups analyses. J Clin Oncol. 2015;33 (suppl; abstr 3510). Compared with FOLFIRI/bevacizumab, FOLFOXIRI/bevacizumab is associated with a non-significant increase of overall survival for patients with BRAFV600E metastatic colorectal cancers (19 months versus 10.7 months; HR 0.54, 95% CI 0.24–1.20).
60.Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.PubMedCentral CrossRef PubMed
61.Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.CrossRef PubMed
62.Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Lee RJ, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol. 2010;28:15s (suppl; abstr 3534).
63.••Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3. In colorectal cancer, BRAFV600E inhibition induces a feedback activation of EGFR. The combination of vemurafenib with an anti-EGFR therapy or a MEK inhibitor may be an effective way to overpass BRAF inhibitor primary resistance in BRAF V600E metastatic CRC .
64.Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRef PubMed
65.Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–51.CrossRef PubMed
66.Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464:427–30.PubMedCentral CrossRef PubMed
67.Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464:431–5.CrossRef PubMed
68.Tabernero J, Chan E, Baselga J, Blay J-Y, Chau I, Hyman DM, et al. VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC). J Clin Oncol. 2014;32:5s. Suppl; abstr 3518.CrossRef
69.Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21:1313–20.CrossRef PubMed
70.Hong D, Morris V, Osta B El, Fu S, Overman M, Piha-Paul S, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers. J Clin Oncol. 2015;33 (suppl; abstr 3511).
71.Corcoran RB, Atreya CE, Falchook GS, Infante JR, Hamid O, Messersmith WA, et al. Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): updated efficacy and biomarker analysis. J Clin Oncol. 2014;32(5s). Suppl; abstr 3517.
72.Atreya C, Van Cutsem E, Bendell J, Andre T, Schellens J, Gordon M, et al. Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;(suppl; abstr 103).
73.Gomez-Roca CA, Delord J, Robert C, Hidalgo M, von Moos R, Arance A, et al. Encorafenib (LGX818), an oral BRAF inhibitor, in patients (pts) with BRAF V600E metastatic colorectal cancer (mCRC): results of dose expansion in an open-label, phase 1 study. Ann Oncol. 2014;25:iv182–3.CrossRef
74.Drug combo beneficial in colorectal cancer. Cancer Discov. 2015;5:102–102.
  • 作者单位：Romain Cohen (1)
    Magali Svrcek (2) (3)
    Chantal Dreyer (1)
    Pascale Cervera (2) (3)
    Alex Duval (4)
    Marc Pocard (5) (6)
    Jean-François Fléjou (2) (3)
    Aimery de Gramont (5) (7)
    Thierry André (1) (3) (4) (5)

    1. Department of Medical Oncology, Hospital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 184, rue du Faubourg-Saint-Antoine, 75012, Paris, France
    2. Department of Pathology, Hospital Saint-Antoine, APHP, 184 rue du Faubourg Saint-Antoine, Paris, 75012, France
    3. University Pierre et Marie Curie (UMPC), Paris VI, 4 Place Jussieu, Paris, 75005, France
    4. INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe “Instabilité des Microsatellites et Cancers,” Equipe labellisée par la Ligue Nationale contre le Cancer, 184 rue du Faubourg Saint-Antoine, Paris, 75012, France
    5. GERCOR, Oncology Multidisciplinary Group, 151 rue du Faubourg Saint Antoine, Paris, 75011, France
    6. Departement of Digestive and Oncologic Surgery, Hospital Lariboisière, APHP, 2 rue Ambroise Paré, Paris, 75010, France
    7. Department of Medical Oncology, Institut Hospitalier Franco-Britannique, 4 rue Kléber, 92300, Levallois-Perret, France
  • 刊物主题：Oncology;
  • 出版者：Springer US
  • ISSN：1534-6269
    • 文摘
    Recently, colorectal cancer (CRC) subtyping consortium identified four consensus molecular subtypes (CMS1–4). CMS1 is enriched for deficient mismatch repair (dMMR) and BRAF V600E tumors. Intriguingly, this subtype has better relapse-free survival but worse overall survival after relapse compared with the other subtypes. Growing evidence is accumulating on the benefit of specific therapeutic strategies such as immune checkpoint inhibition therapy in dMMR tumors and mitogen-activated protein kinase (MAPK) pathway targeted therapy in tumors harboring BRAF V600E mutation. After reviewing dMMR prognostic value, immune checkpoints as major targets for dMMR carcinomas will be highlighted. Following, BRAF V600E prognostic impact will be reviewed and therapeutic strategies with the combination of cytotoxic agents and especially the combinations of BRAF and MAPK inhibitors will be discussed. Keywords Microsatellite instability BRAF mutation Immune checkpoint PD-1 PD-L1

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址：北京市海淀区学院路29号 邮编：100083

    电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700